These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8210624)
1. [Plasma fibronectin in chronic liver diseases]. Soresi M; Di Martino D; Montalto G; Carroccio A; Ruggeri MI; Bascone F; Ippolito S; Notarbartolo A Recenti Prog Med; 1993 Sep; 84(9):602-7. PubMed ID: 8210624 [TBL] [Abstract][Full Text] [Related]
2. [Plasma fibronectin in chronic liver disease--marker of fibrosis?]. Simon K; Zalewska M; Gładysz A; Rotter K; Piszko P; Głowacki A Przegl Lek; 1995; 52(4):129-32. PubMed ID: 7638358 [TBL] [Abstract][Full Text] [Related]
3. [Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases]. Tomihira M Fukuoka Igaku Zasshi; 1991 Jan; 82(1):21-30. PubMed ID: 1708742 [TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor-alpha levels in hepatitis B virus-related chronic active hepatitis and liver cirrhosis and its relationship to Knodell and Child-Pugh scores. Kiki I; Yilmaz O; Erdem F; Gundogdu M; Demircan B; Bilici M Int J Clin Pract; 2006 Sep; 60(9):1075-9. PubMed ID: 16939549 [TBL] [Abstract][Full Text] [Related]
5. Plasma levels of fibronectin in patients with chronic viral and alcoholic liver disease. Grieco A; Matera A; Di Rocco P; Marcoccia S; Giancaterini A; Alfei B; Addolorato G; Varlese F; Gasbarrini G Hepatogastroenterology; 1998; 45(23):1731-6. PubMed ID: 9840137 [TBL] [Abstract][Full Text] [Related]
6. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Koruk M; Onuk MD; Akçay F; Savas MC Hepatogastroenterology; 2002; 49(48):1645-8. PubMed ID: 12397754 [TBL] [Abstract][Full Text] [Related]
7. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Luo JC; Hwang SJ; Chang FY; Chu CW; Lai CR; Wang YJ; Lee PC; Tsay SH; Lee SD Hepatogastroenterology; 2002; 49(44):478-81. PubMed ID: 11995477 [TBL] [Abstract][Full Text] [Related]
8. [Factors influencing the effect of ursodeoxycholic acid therapy in chronic hypertransaminasemia]. Buongiorno G; Quaranta GM; Guerra V; Misciagna G; Manghisi OG Recenti Prog Med; 1992 May; 83(5):298-302. PubMed ID: 1439111 [TBL] [Abstract][Full Text] [Related]
9. Serum iron parameters in patients with alcoholic and chronic cirrhosis and hepatitis. Jurczyk K; Wawrzynowicz-Syczewska M; Boroń-Kaczmarska A; Sych Z Med Sci Monit; 2001; 7(5):962-5. PubMed ID: 11535942 [TBL] [Abstract][Full Text] [Related]
10. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634 [TBL] [Abstract][Full Text] [Related]
11. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Cicognani C; Malavolti M; Morselli-Labate AM; Zamboni L; Sama C; Barbara L Arch Intern Med; 1997 Apr; 157(7):792-6. PubMed ID: 9125012 [TBL] [Abstract][Full Text] [Related]
13. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]. Wu XR; Wang Q; Shi SS; Lu MH; Guo WD Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106 [TBL] [Abstract][Full Text] [Related]
14. Profiles of plasma amino acids in fasted patients with various liver diseases. Fujinami S; Hijikata Y; Shiozaki Y; Sameshima Y Hepatogastroenterology; 1990 Dec; 37 Suppl 2():81-4. PubMed ID: 2083940 [TBL] [Abstract][Full Text] [Related]
15. [Diagnostic importance of fibronectin in chronic liver diseases]. Golubović M; Majkić-Singh N; Marković S; Sumarac Z; Obradović I Med Pregl; 1999; 52(1-2):35-8. PubMed ID: 10352502 [TBL] [Abstract][Full Text] [Related]
16. [Biochemical markers of fibrosis in chronic hepatitis and liver cirrhosis of viral origin]. Kozłowska J; Łoch T; Jabłońska J; Cianciara J Przegl Epidemiol; 2001; 55(4):451-8. PubMed ID: 11921731 [TBL] [Abstract][Full Text] [Related]
17. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449 [TBL] [Abstract][Full Text] [Related]
18. [Study on the influence factors of the serum fibrosis markers]. Cai WM; Tao J; Weng HL; Liu RH Zhonghua Gan Zang Bing Za Zhi; 2003 Jan; 11(1):23-5. PubMed ID: 12546736 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of oxidant stress in Wilson's disease and non-Wilsonian chronic liver disease in childhood. Dalgiç B; Sönmez N; Biberoğlu G; Hasanoğlu A; Erbaş D Turk J Gastroenterol; 2005 Mar; 16(1):7-11. PubMed ID: 16252181 [TBL] [Abstract][Full Text] [Related]
20. Fibronectin levels in chronic viral hepatitis and response of this protein to interferon therapy. Kandemir O; Polat G; Sahin E; Bagdatoglu O; Camdeviren H; Kaya A Hepatogastroenterology; 2004; 51(57):811-4. PubMed ID: 15143922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]